Armed With Peoples Genetics Technology, Beckman Will Soon Take Aim at Transgenomic | GenomeWeb

If you can’t beat them, avoid them?

This appeared to be Beckman Coulter’s strategy a couple of weeks ago when it decided to buy Peoples Genetics’ constant denaturant capillary electrophoresis technology.

The technology, which enables researchers to identify gene mutations in large pools of DNA, will enable Beckman to compete with Applied Biosystems — the “gorilla in the sequencing market,” according to Beckman treasurer Paul Glyer — without actually going head-to-head with the company.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.